Consensus IntelGenx Technologies Corp.

Equities

IGXT

US45822R1014

Market Closed - OTC Markets Other stock markets 20:59:28 03/05/2024 BST			5-day change	1st Jan Change
0.179 ^USD	+0.28%		+9.15%	+29.62%

04-08	Intelgenx Announces First Parkinson?S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ?Montpark? Clinical Trial	CI
04-05	IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	MT

Evolution of the average Target Price on IntelGenx Technologies Corp.

Price target over the last 5 years

History of analyst recommendation changes

b4db80677a5f89abe7a1ae0a0913939.viIsQeENBNCE68MDHtOou5sa9FwcXbp4x2q4y62qQnw.zkVWKrZ4M6TN3vpxd57s2NF0rSVaDNAMgSnQrfLTbw3tWEYppUZ1lPemlg~7bf0232fde66b3cd013547a96aedd6c7

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.1619

Average target price